LSX2026: Addressing adult eye cancer, with Roi Raz

At the LSX World Congress in Lisbon this year, web editor Nicole Raleigh spoke with Roi Raz, CEO of ReBio Pharma, a preclinical stage biotechnology company that has developed SiSu, an injectable, bioresorbable sustained release delivery platform for ophthalmic therapeutics.

The conversation centres on ReBio’s work in uveal melanoma, the most common eye cancer in adults, and its broader pipeline. Raz also discusses the Congress at large and his insights from the event.

Watch this and other conversations from LSX World Congress on our Spotlight On BIO-Europe page.